Louisiana SB253 prohibits healthcare providers from prescribing peptides shipped from FDA-registered facilities.
Louisiana SB253 mandates that healthcare providers with prescriptive authority cannot provide patients with peptides shipped from FDA-registered 503B facilities or 503A compounding pharmacies sourcing active pharmaceutical ingredients from FDA-registered manufacturers. The prescribing provider must ensure that any peptides prescribed are not on the FDA's prohibited compounding list. This regulation takes effect on August 1, 2026.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
Analyze for Free
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.